FBXO31 determines poor prognosis in esophageal squamous cell carcinoma

Ryunosuke Kogo, Koshi Mimori, Fumiaki Tanaka, Shizuo Komune, Masaki Mori

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Cyclin D1 plays important roles in esophageal squamous cell carcinoma (ESCC) cases by amplification of the 11q13.3 locus. FBXO31 is a subunit of the SCF ubiquitin ligase, which targets cyclin D1 for degradation. In this study, we clarified the clinical significance of FBXO31 and characterized the association between cyclin D1 and FBXO31 in ESCC cases. Total RNA was extracted from tumor tissues obtained from 68 ESCC patients who underwent surgical resection. FBXO31 expression levels were determined by quantitative RT-PCR, and both FBXO31 and cyclin D1 protein expression and localization were evaluated by immunohistochemistry (IHC). Furthermore, using CGH and gene expression array data of another subset, we validated the association between cyclin D1 genomic amplification and FBXO31 expression levels. Higher FBXO31 expression levels significantly correlated with depth of tumor invasion and clinical stage (P<0.05). In addition, the FBXO31 high expression group showed a significantly poorer prognosis than the low expression group (P<0.001). Multivariate analysis indicated that FBXO31 expression was an independent prognostic factor [relative risk (RR): 1.79, confidence interval (CI): 1.14-3.01, P=0.01]. Using IHC, concordant expression was observed between cyclin D1 and FBXO31 in the nucleus and cytoplasm, respectively. CGH array indicated that cases having cyclin D1 with increased copy number were significantly associated with elevated FBXO31 expression levels (P<0.05). FBXO31 could be a novel and robust prognostic marker for ESCC.

Original languageEnglish
Pages (from-to)155-159
Number of pages5
JournalInternational journal of oncology
Volume39
Issue number1
DOIs
Publication statusPublished - Jul 1 2011

Fingerprint

Cyclin D1
SKP Cullin F-Box Protein Ligases
Immunohistochemistry
Esophageal Squamous Cell Carcinoma
Neoplasms
Cytoplasm
Multivariate Analysis
RNA
Confidence Intervals
Gene Expression
Polymerase Chain Reaction
Proteins

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

FBXO31 determines poor prognosis in esophageal squamous cell carcinoma. / Kogo, Ryunosuke; Mimori, Koshi; Tanaka, Fumiaki; Komune, Shizuo; Mori, Masaki.

In: International journal of oncology, Vol. 39, No. 1, 01.07.2011, p. 155-159.

Research output: Contribution to journalArticle

Kogo, Ryunosuke ; Mimori, Koshi ; Tanaka, Fumiaki ; Komune, Shizuo ; Mori, Masaki. / FBXO31 determines poor prognosis in esophageal squamous cell carcinoma. In: International journal of oncology. 2011 ; Vol. 39, No. 1. pp. 155-159.
@article{4f17cbc55e424481b5e7193e829b8635,
title = "FBXO31 determines poor prognosis in esophageal squamous cell carcinoma",
abstract = "Cyclin D1 plays important roles in esophageal squamous cell carcinoma (ESCC) cases by amplification of the 11q13.3 locus. FBXO31 is a subunit of the SCF ubiquitin ligase, which targets cyclin D1 for degradation. In this study, we clarified the clinical significance of FBXO31 and characterized the association between cyclin D1 and FBXO31 in ESCC cases. Total RNA was extracted from tumor tissues obtained from 68 ESCC patients who underwent surgical resection. FBXO31 expression levels were determined by quantitative RT-PCR, and both FBXO31 and cyclin D1 protein expression and localization were evaluated by immunohistochemistry (IHC). Furthermore, using CGH and gene expression array data of another subset, we validated the association between cyclin D1 genomic amplification and FBXO31 expression levels. Higher FBXO31 expression levels significantly correlated with depth of tumor invasion and clinical stage (P<0.05). In addition, the FBXO31 high expression group showed a significantly poorer prognosis than the low expression group (P<0.001). Multivariate analysis indicated that FBXO31 expression was an independent prognostic factor [relative risk (RR): 1.79, confidence interval (CI): 1.14-3.01, P=0.01]. Using IHC, concordant expression was observed between cyclin D1 and FBXO31 in the nucleus and cytoplasm, respectively. CGH array indicated that cases having cyclin D1 with increased copy number were significantly associated with elevated FBXO31 expression levels (P<0.05). FBXO31 could be a novel and robust prognostic marker for ESCC.",
author = "Ryunosuke Kogo and Koshi Mimori and Fumiaki Tanaka and Shizuo Komune and Masaki Mori",
year = "2011",
month = "7",
day = "1",
doi = "10.3892/ijo.2011.1018",
language = "English",
volume = "39",
pages = "155--159",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - FBXO31 determines poor prognosis in esophageal squamous cell carcinoma

AU - Kogo, Ryunosuke

AU - Mimori, Koshi

AU - Tanaka, Fumiaki

AU - Komune, Shizuo

AU - Mori, Masaki

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Cyclin D1 plays important roles in esophageal squamous cell carcinoma (ESCC) cases by amplification of the 11q13.3 locus. FBXO31 is a subunit of the SCF ubiquitin ligase, which targets cyclin D1 for degradation. In this study, we clarified the clinical significance of FBXO31 and characterized the association between cyclin D1 and FBXO31 in ESCC cases. Total RNA was extracted from tumor tissues obtained from 68 ESCC patients who underwent surgical resection. FBXO31 expression levels were determined by quantitative RT-PCR, and both FBXO31 and cyclin D1 protein expression and localization were evaluated by immunohistochemistry (IHC). Furthermore, using CGH and gene expression array data of another subset, we validated the association between cyclin D1 genomic amplification and FBXO31 expression levels. Higher FBXO31 expression levels significantly correlated with depth of tumor invasion and clinical stage (P<0.05). In addition, the FBXO31 high expression group showed a significantly poorer prognosis than the low expression group (P<0.001). Multivariate analysis indicated that FBXO31 expression was an independent prognostic factor [relative risk (RR): 1.79, confidence interval (CI): 1.14-3.01, P=0.01]. Using IHC, concordant expression was observed between cyclin D1 and FBXO31 in the nucleus and cytoplasm, respectively. CGH array indicated that cases having cyclin D1 with increased copy number were significantly associated with elevated FBXO31 expression levels (P<0.05). FBXO31 could be a novel and robust prognostic marker for ESCC.

AB - Cyclin D1 plays important roles in esophageal squamous cell carcinoma (ESCC) cases by amplification of the 11q13.3 locus. FBXO31 is a subunit of the SCF ubiquitin ligase, which targets cyclin D1 for degradation. In this study, we clarified the clinical significance of FBXO31 and characterized the association between cyclin D1 and FBXO31 in ESCC cases. Total RNA was extracted from tumor tissues obtained from 68 ESCC patients who underwent surgical resection. FBXO31 expression levels were determined by quantitative RT-PCR, and both FBXO31 and cyclin D1 protein expression and localization were evaluated by immunohistochemistry (IHC). Furthermore, using CGH and gene expression array data of another subset, we validated the association between cyclin D1 genomic amplification and FBXO31 expression levels. Higher FBXO31 expression levels significantly correlated with depth of tumor invasion and clinical stage (P<0.05). In addition, the FBXO31 high expression group showed a significantly poorer prognosis than the low expression group (P<0.001). Multivariate analysis indicated that FBXO31 expression was an independent prognostic factor [relative risk (RR): 1.79, confidence interval (CI): 1.14-3.01, P=0.01]. Using IHC, concordant expression was observed between cyclin D1 and FBXO31 in the nucleus and cytoplasm, respectively. CGH array indicated that cases having cyclin D1 with increased copy number were significantly associated with elevated FBXO31 expression levels (P<0.05). FBXO31 could be a novel and robust prognostic marker for ESCC.

UR - http://www.scopus.com/inward/record.url?scp=79956042390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956042390&partnerID=8YFLogxK

U2 - 10.3892/ijo.2011.1018

DO - 10.3892/ijo.2011.1018

M3 - Article

C2 - 21537837

AN - SCOPUS:79956042390

VL - 39

SP - 155

EP - 159

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 1

ER -